Charles River Laboratories International, Inc. (NYSE:CRL) Shares Bought by Lazard Asset Management LLC

Lazard Asset Management LLC raised its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 42.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,757 shares of the medical research company’s stock after purchasing an additional 3,194 shares during the period. Lazard Asset Management LLC’s holdings in Charles River Laboratories International were worth $1,985,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of CRL. D1 Capital Partners L.P. acquired a new stake in Charles River Laboratories International in the 4th quarter valued at about $172,752,000. Norges Bank purchased a new position in shares of Charles River Laboratories International in the 4th quarter valued at about $98,886,000. Wellington Management Group LLP increased its holdings in shares of Charles River Laboratories International by 9.0% in the 4th quarter. Wellington Management Group LLP now owns 4,076,426 shares of the medical research company’s stock valued at $752,508,000 after acquiring an additional 335,658 shares during the last quarter. Raymond James Financial Inc. purchased a new position in shares of Charles River Laboratories International in the 4th quarter valued at about $42,776,000. Finally, Alyeska Investment Group L.P. purchased a new position in shares of Charles River Laboratories International in the 4th quarter valued at about $36,968,000. Institutional investors and hedge funds own 98.91% of the company’s stock.

Charles River Laboratories International Trading Up 1.5%

Shares of CRL stock opened at $141.00 on Friday. The business’s 50 day moving average is $135.43 and its two-hundred day moving average is $164.86. Charles River Laboratories International, Inc. has a twelve month low of $91.86 and a twelve month high of $254.15. The company has a market capitalization of $6.93 billion, a P/E ratio of 940.00, a price-to-earnings-growth ratio of 4.54 and a beta of 1.50. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share for the quarter, beating the consensus estimate of $2.06 by $0.28. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The company had revenue of $984.17 million for the quarter, compared to the consensus estimate of $942.34 million. During the same period last year, the business posted $2.27 EPS. The company’s revenue was down 2.7% on a year-over-year basis. Equities analysts forecast that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on CRL shares. William Blair downgraded Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 22nd. TD Cowen upgraded Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $179.00 price objective on the stock in a report on Wednesday. JPMorgan Chase & Co. dropped their price objective on Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating on the stock in a report on Thursday, February 20th. Morgan Stanley dropped their price objective on Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 5th. Finally, Mizuho dropped their price objective on Charles River Laboratories International from $175.00 to $155.00 and set a “neutral” rating on the stock in a report on Wednesday, April 9th. One equities research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $172.31.

Insider Buying and Selling at Charles River Laboratories International

In related news, COO Birgit Girshick bought 1,514 shares of the stock in a transaction on Thursday, February 20th. The shares were bought at an average cost of $164.63 per share, for a total transaction of $249,249.82. Following the purchase, the chief operating officer now owns 55,058 shares of the company’s stock, valued at $9,064,198.54. This trade represents a 2.83% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Joseph W. Laplume sold 500 shares of Charles River Laboratories International stock in a transaction that occurred on Tuesday, May 13th. The shares were sold at an average price of $145.41, for a total value of $72,705.00. Following the completion of the transaction, the executive vice president now owns 19,513 shares in the company, valued at $2,837,385.33. This trade represents a 2.50% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 5,040 shares of company stock worth $807,407. 1.30% of the stock is currently owned by insiders.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).